COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS

Patent number:

US2022016080

Galicia.svg
No items found.

The present invention provides a class of compounds, which includes enantiomers and pharmaceutically acceptable salts thereof, that selectively and effectively inhibit Hakai-mediated ubiquitination, preferably without affecting Hakai protein levels, thereby representing excellent anti-cancer drugs useful in the treatment of a variety of cancers, such as carcinomas, in particular, tumors arising from the epithelial layers of the gastrointestinal track including month (oral cancer), esophagus, stomach, and small and large intestines (such as rectal or colon cancer). It also includes skin cancer, mammary gland (breast cancer), pancreas cancer, lung cancer, head and neck cancer, liver cancer, ovary cancer, cervix cancer, uterus cancer, gallbladder cancer, penile cancer, and urinary bladder cancer (such as renal, prostate or bladder cancer).

Countries:
Spain
Regions:
Galicia
Centers:
FUND PROFESOR NOVOA SANTOS, FUNDACION PROFESOR NOVOA SANTOS
Other entities:
Sectors:
Health
Subsectors:
Pharmaceuticals
TRL Level:
TRL 3 – experimental proof of concept
BRL Level:
BRL3. Draft of Business model described market potential & competitive overview
PDF Link:
Download here
Video Link:
Watch it here
Sustainable Development Goal:
Applications

Diana terapéutica orientada a la prevención y al tratamiento del cáncer.

Comments

Other related patents

Health

METHOD AND SYSTEM FOR PREDICTING GLUCOSE VALUES AND ALERT GENERATION OF HYPOGLYCAEMIA AND HYPERGLYCEMIA (MACHINE-TRANSLATION BY GOOGLE TRANSLATE, NOT LEGALLY BINDING)

Countries
Spain
Know more
Health

Rapid and accurate breast cancer cell diagnosis via digital holographic microscopy (DHM)

Countries
Spain
Know more
Health

IN VITRO METHOD FOR THE DIAGNOSIS OR PROGNOSIS OF BREAST CANCER

Countries
Spain
Know more
Get back to patents directory